Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Samonigg, H; Kasparek, AK; Stöger, H; Schmid, M; Eber, B; Stark, G; Weinrauch, V; Pfeiffer, K; Smola, M; Steindorfer, P.
4'-O-tetrahydropyranyl-doxorubicin in advanced breast cancer: a phase II study.
Cancer Chemother Pharmacol. 1990; 26(4):293-296
Doi: 10.1007/BF02897233
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Führende Autor*innen der Med Uni Graz
- Samonigg Hellmut
- Co-Autor*innen der Med Uni Graz
- Kasparek Anne-Katrin
- Smola Michael
- Stöger Herbert
- Weinrauch Vera
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- In a phase II study, 35 patients with advanced breast cancer were treated with 4'-O-tetrahydropyranyl-doxorubicin (THP-DXR) (70 mg/m2 i.v. on day 1); treatment was repeated every 3 weeks. Eight patients had failed prior chemotherapy for advanced disease. A total of 34 patients were evaluable for response. After a median of 10 treatment courses (range, 3-15), objective tumor response was seen in 59% (20 of 34 patients) (95% confidence limits, 42%-75%). In all, 17 partial remissions and 3 complete remissions were observed; stable disease occurred in 13 patients. The median duration of response was 42+ weeks (range, 21 - 77+ weeks). The dose-limiting side effects were leukopenia (26 patients, WHO grade III-IV) and thrombocytopenia (9 patients, WHO grade II-IV). Nausea/vomiting was experienced by 34 patients; in 18, it reached WHO grade II-III. Other treatment-related side effects included alopecia (WHO grade II-III) in 26 patients and stomatitis and diarrhea (WHO grade I-III) in 9 patients. At cumulative doses of THP-DXR of at least 700 mg/m2 (range, 700-1,050 mg/m2), no signs of congestive heart failure were observed. We conclude that THP-DXR is effective for first- and second-line chemotherapy in advanced breast cancer and that side effects are manageable.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Breast Neoplasms - drug therapy
- Breast Neoplasms - pathology
- Doxorubicin - adverse effects
- Doxorubicin - analogs & derivatives
- Doxorubicin - therapeutic use
- Drug Evaluation -
- Female -
- Humans -
- Leukocyte Count -
- Leukopenia - chemically induced
- Male -
- Middle Aged -
- Platelet Count -
- Survival Analysis -